<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1809">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390061</url>
  </required_header>
  <id_info>
    <org_study_id>2020-002035-30</org_study_id>
    <nct_id>NCT04390061</nct_id>
  </id_info>
  <brief_title>TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia</brief_title>
  <acronym>TOFACoV-2</acronym>
  <official_title>TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With Early Onset SARS-CoV2 (COVID-19) Interstitial Pneumonia:a Multicenter Randomized Controlled Open Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Politecnica delle Marche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera Ospedali Riuniti Marche Nord</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Civile Santo Spirito, Pescara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università Magna Grecia, Catanzaro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASST Papa Giovanni XXIII, Bergamo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero Universitaria Policlinico Umberto I, Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASST Cremona, Cremona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale di Circolo e Fondazione Macchi, Varese</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Università Politecnica delle Marche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multifocal interstitial pneumonia represents the most common cause of admission in intensive
      care units and death in SARS-CoV2 infections. In our Hospital, similarly to what reported in
      literature, up to 25% of admitted patients with pneumonitis requires mechanical ventilation
      or oro-tracheal intubation within 5-10 days. No established treatment is available for this
      condition. Preliminary evidence is accumulating about the efficacy of an aggressive treatment
      of the corona virus-induced inflammation and, in particular, investigators believe that
      blocking JAK1 is clinically rewarding in down-regulating IL-6 driven inflammation in patients
      with corona-virus infection. Thus, investigators designed a randomized controlled trial to
      test the hypothesis that adding Tofacitinib to the standard treatment in the early phase of
      COVID related pneumonitis could prevent the development of severe respiratory failure needing
      mechanical ventilation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter open label randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of severe Respiratory Failure requiring mechanical ventilation</measure>
    <time_frame>14 days</time_frame>
    <description>Rate of patients needing mechanical ventilation to maintain PaO2/FIO2&gt;150</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention of need of ICU admission</measure>
    <time_frame>28 days</time_frame>
    <description>Rate of patients needing admission to the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevention of COVID-19 related Deaths</measure>
    <time_frame>28 days</time_frame>
    <description>Rate of patients who die due to COVID-19 related conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of predictors of outcome</measure>
    <time_frame>14 days</time_frame>
    <description>Role of some clinical and laboratory factors in predicting outcome (Age, sex, smoking status, Body Mass Index (BMI), Comorbidities (Diabetes, number of comorbidities), Respiratory Failure at admission defined as PaO2/FiO2&lt;300, Extension of Ct-scan involvement, basal level of serum IL-6, vW-Factor, Thrombomodulin, KL-6, sACE2 and SP-D )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Rate of severe drug-related adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Pneumonitis, Interstitial</condition>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>tofacitinib+HYQ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tofacitinib 10mg cp twice a day + Hydroxychloroquine 200mg cp three times a day, both for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine 200mg cp three times a day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Jak-1/3 inhibitor</description>
    <arm_group_label>tofacitinib+HYQ</arm_group_label>
    <other_name>Xeljanz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Standard Therapy</description>
    <arm_group_label>Hydroxychloroquine</arm_group_label>
    <arm_group_label>tofacitinib+HYQ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SARS-CoV2 Infection diagnosed by rt-PCR

          -  CT-scan confirmed interstitial pneumonia

          -  Hospital admission from less than 24h

          -  P/F ratio &gt;150 mmHg

          -  Written Informed Consent

        Exclusion Criteria:

          -  Age &lt;18 ys or &gt;65

          -  Patients in mechanical ventilation at time of admission

          -  Severe Hearth failure (NYHA 3 or 4)

          -  QTc &gt; 470 ms or &gt;500 ms in wide QRS patients

          -  Severe History of Chronic Ischemic Heart Disease, defined as history of Major Adverse
             Cardiovascular Event and/or recent (one year) revascularization.

          -  History of recurrent Deep Venous Thrombosis and Pulmonary Embolism or established
             thrombophilic conditions (e.g. history of anti-phospholipid antibodies, …)

          -  Active Bacterial or Fungal Infection

          -  Hematological cancer

          -  Metastatic or intractable cancer

          -  Pre-existent neurodegenerative disease

          -  Severe Hepatic Impairment,

          -  History of acute diverticular disease or intestinal perforation

          -  HBsAg positive and/or HBV-DNA positive patients

          -  Severe Renal Failure (Creatinine Clearance &lt;30ml/h)

          -  Active Herpes zoster infection

          -  Patients with active or latent TB

          -  Severe anemia (Hb&lt;9g/dl)

          -  Lymphocyte count below 750/mcl

          -  Neutrophil count below 1000/mcl

          -  Platelet count below 50000/mcl

          -  Pregnancy or Lactation

          -  History of intolerance to the experimental drugs or excipients

          -  Degenerative maculopathy or other relevant retinal disease

          -  Inability to give informed consent (severe transitory or permanent mental impairment,
             incapacitation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Armando Gabrielli, MD</last_name>
    <phone>0712206104</phone>
    <email>a.gabrielli@staff.univpm.it</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Politecnica delle Marche</investigator_affiliation>
    <investigator_full_name>Armando Gabrielli</investigator_full_name>
    <investigator_title>Full Professor Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

